342
Participants
Start Date
June 30, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
Symptom-based adjustment
Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Biomarker-based adjustment
Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Guideline-based adjustment
Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Columbia University Medical Center, New York
Wake Forest University Health Sciences, Winston-Salem
Duke University Medical Center, Durham
University of Wisconsin, Madison, Madison
Washington University, St. Louis, St Louis
University of Texas Medical Branch, Galveston
National Jewish Medical and Research Center, Denver
University of California, San Diego, San Diego
University of California, San Francisco, San Francisco
Brigham & Women's Hospital, Boston
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Milton S. Hershey Medical Center
OTHER